Antibiotic May Help Treat Refractory HS
Patients with severe, refractory hidradenitis suppurativa (HS) may benefit from ertapenem (Invanz) therapy, according to the findings of a recent study.
In the retrospective study, the researchers examined medical charts of 36 patients with Hurley stage 2 or 3 HS who were treated with intravenous ertapenem between March 2013 and December 2016 (22 were female). Additionally, the researchers conducted telephone interviews that included questions on satisfaction, quality of life changes, and disease state changes while receiving ertapenem therapy.
HS Linked to Increased Risk for Crohn Disease
HS Linked to Negative Body Image
Overall, 35 (97.2%) patients experienced improvements in HS while receiving ertapenem therapy. Of the 28 patients who participated in the phone interviews, 20 (71.4%) were very satisfied or satisfied and 85.7% experienced improvements in quality of life.
“Following ertapenem therapy, patients reported improvements in quality of life,” the researchers concluded. “This treatment appears promising as an adjunct to biologics or as a bridge to surgery in the treatment of severe, refractory HS.”
Braunberger TL, Nartker NT, Nicholson CL, et al. Ertapenem–a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa [published online May 17, 2018]. Int J Dermatol. https://doi.org/10.1111/ijd.14036